NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Asher Biotherapeutics

Asher Biotherapeutics

Private
South San Francisco, CaliforniaHealthcare & Life Scienceshttps://asherbio.com/

Last Round

Series C

Apr 16, 2024

Total Funding Raised

$218.15M

Company Overview

Asher Biotherapeutics is a biotechnology company that develops precisely targeted immunotherapies for cancer and other diseases using a proprietary cis-targeting platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

immunotherapycis-targeted immunotherapyprecision medicinecytokine therapybiotechsolid tumor treatmentnext-gen immunotherapydrug discoveryclinical trialoncology pipelineprotein engineeringbiologicscancer drug developmenttherapeutic indexclinical-stage biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Asher Biotherapeutics Comparables

Compare Asher Biotherapeutics with similar companies based on industry and business-model similarity.

Asher Biotherapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Synthekine
91%
Bright Peak Therapeutics
89%
Inhibrx
83%

Asher Biotherapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CApr 16, 2024
Series BSep 1, 2021
Series AMar 23, 2021
AcceleratorAug 21, 2019

Key People

Founding team and executive leadership

Craig Gibbs

Chief Executive Officer

Executive Team

Kyle Elrod

Chief Operating Officer

Executive Team

Asher Biotherapeutics Investors

Notable investors and investment history

Asher Biotherapeutics investors
InvestorRounds
Janus Henderson GroupSeries C, Series B
RA Capital ManagementSeries B, Series C
Boxer CapitalSeries A, Series C, Series B
Invus OpportunitiesSeries A, Series B
Logos CapitalSeries B
Alexandria Venture InvestmentsSeries B
Y CombinatorSeries A, Accelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 16, 2024

    $55M round led by RA Capital Management.

  • Sep 1, 2021

    $108M round led by Wellington Management.

Asher Biotherapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Asher Biotherapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Asher Biotherapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSouth San Francisco, California
Employee Range15
Year Founded2019
Last FundingApr 16, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.